Guido Guidesi, Councilor for Economic Development of the Lombardy Region, visits IBSA Farmaceutici’s Lodi production site06 August 2021
On July 23, the Councilor of the Lombardy Region, Guido Guidesi, visited the major Lodi companies, including a stop at the IBSA Farmaceutici’s headquarters in Lodi, to see the facilities of a thriving production reality within the Italian pharmaceutical sector.
Luca Crippa – CEO and Managing Director – welcomed the Councilor for a discussion on the Lodi production realities, on IBSA’s significant role in this context and on the renewed commitment of the Company to the Health System. The meeting was also attended by the mayor of Lodi Sara Casanova, who met the employees and saw up close the commitment they constantly kept also throughout the pandemic period.
IBSA does research and produces drugs in Italy, and over the years has established itself as a leading scientific, economic and industrial reality, developing products that reach international markets, thus exporting the Made in Italy excellence worldwide. Councilor Guidesi recognized the role and value of the activities implemented by the Company, and the concrete support it provides not only to the industry, but also to the local reality in terms of investments and scientific and technological know-how. Indeed, the Company recently announced a € 15 million investment plan, in confirmation of the fact that IBSA did not stop during the crisis generated by the global pandemic, but instead decided once again to believe in our Country and concretely support it.
To conclude the meeting, Councilor Guidesi – together with Luca Crippa, Antonio Melli (CFO of the IBSA Group) and Roberto Maglio (Head of IBSA Farmaceutici’s Italian manufacturing) – visited the production plants, in order to know firsthand the innovation and cutting-edge technology that distinguish the Company, allowing it to develop “drugs in their best form”, that is, based on new forms of administration and delivery systems that allow for a better and more effective adherence to therapy by the patient.
You can find the press review here